QQ客服 官方微博 反馈留言

	Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study
	Li, Huiping; Zhang, Qingyuan; Li, Wei; Wang, Shusen; Liao, Ning; Shen, Peng; Shao, Bin; Zhao, Wenhui; Sun, Wan; Yan, Ping
	2017
卷号	18页码:S7-S7
ISSN号	1470-2045
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6363307
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Li, Huiping,Zhang, Qingyuan,Li, Wei,et al. Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study[J],2017,18:S7-S7.
APA	Li, Huiping.,Zhang, Qingyuan.,Li, Wei.,Wang, Shusen.,Liao, Ning.,...&Xu, Binghe.(2017).Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study.,18,S7-S7.
MLA	Li, Huiping,et al."Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study".18(2017):S7-S7.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。